HeartSciences (NASDAQ:HSCS) Posts Quarterly Earnings Results, Misses Estimates By $0.22 EPS

HeartSciences (NASDAQ:HSCS) posted its quarterly earnings data on Thursday. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.22), Zacks reports.

HeartSciences Price Performance

Shares of HeartSciences stock traded down $0.05 during trading on Friday, hitting $2.39. 8,205 shares of the company’s stock traded hands, compared to its average volume of 86,167. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.19 and a quick ratio of 1.04. The firm’s fifty day moving average price is $2.27 and its 200 day moving average price is $2.50. HeartSciences has a twelve month low of $1.63 and a twelve month high of $4.30. The company has a market cap of $7.60 million, a PE ratio of -0.61 and a beta of 1.78.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of HeartSciences in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $8.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in HeartSciences stock. Geode Capital Management LLC acquired a new stake in shares of HeartSciences Inc. (NASDAQ:HSCS) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 11,599 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned approximately 0.51% of HeartSciences at the end of the most recent quarter. Hedge funds and other institutional investors own 17.24% of the company’s stock.

HeartSciences Company Profile

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.